Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 2,723,912 shares, an increase of 45.6% from the October 15th total of 1,871,370 shares. Based on an average daily volume of 832,548 shares, the days-to-cover ratio is presently 3.3 days. Currently, 6.5% of the company’s stock are short sold.
A number of analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $4.50 price objective on shares of Eyepoint Pharmaceuticals in a research note on Monday, October 1st. B. Riley raised their price objective on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Finally, Zacks Investment Research lowered shares of Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 17th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Eyepoint Pharmaceuticals has an average rating of “Buy” and an average target price of $5.50.
Hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC bought a new stake in shares of Eyepoint Pharmaceuticals in the third quarter worth approximately $134,000. Regal Investment Advisors LLC bought a new stake in shares of Eyepoint Pharmaceuticals in the third quarter worth approximately $196,000. FineMark National Bank & Trust bought a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $118,000. California Public Employees Retirement System bought a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $135,000. Finally, Creative Planning bought a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $162,000. Hedge funds and other institutional investors own 62.85% of the company’s stock.
NASDAQ:EYPT opened at $2.30 on Friday. The stock has a market cap of $172.87 million, a price-to-earnings ratio of -3.97 and a beta of 1.73. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.84 and a quick ratio of 1.84. Eyepoint Pharmaceuticals has a fifty-two week low of $0.93 and a fifty-two week high of $3.94.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 377.64%. The firm had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.70 million. Equities research analysts expect that Eyepoint Pharmaceuticals will post -0.42 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/eyepoint-pharmaceuticals-inc-eypt-short-interest-update.html.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.